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20-Hydroxyeicosatetraenoic acid (20-HETE) production is
increased in ischemic kidney tissue and may contribute to
ischemia/reperfusion (I/R) injury by mediating
vasoconstriction and inflammation. To test this hypothesis,
uninephrectomized male Lewis rats were exposed to
warm ischemia following pretreatment with either an
inhibitor of 20-HETE synthesis (HET0016), an antagonist
(20-hydroxyeicosa-6(Z),15(Z)-dienoic acid), an agonist
(20-hydroxyeicosa-5(Z),14(Z)-dienoic acid), or vehicle via the
renal artery and the kidneys were examined 2 days after
reperfusion. Pretreatment with either the inhibitor or the
antagonist attenuated I/R-induced renal dysfunction as
shown by improved creatinine clearance and decreased
plasma urea levels, compared to controls. The inhibitor and
antagonist also markedly reduced tubular lesion scores,
inflammatory cell infiltration, and tubular epithelial cell
apoptosis. Administering the antagonist accelerated the
recovery of medullary perfusion, as well as renal medullary
and cortical re-oxygenation, during the early reperfusion
phase. In contrast, the agonist did not improve renal injury
and reversed the beneficial effect of the inhibitor. Thus,
20-HETE generation and its action mediated kidney injury
due to I/R. Whether or not these effects are clinically
important will need to be tested in appropriate human
studies.
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Ischemia/reperfusion (I/R)-induced acute kidney injury (AKI)
leads to increased morbidity and mortality, particularly
after cardiovascular surgery and kidney transplantation.1–3
I/R-induced mechanisms include persistent vasoconstriction,
inflammation, endothelial dysfunction, and tubular injury.4,5
20-Hydroxyeicosatetraenoic acid (20-HETE), the product of
cytochrome P450 (CYP)-catalyzed o-hydroxylation of arachido-
nic acid, modulates renal vascular and tubular function.6,7 Major
sites of 20-HETE generation are preglomerular microvessels,
where 20-HETE mediates constriction by inhibiting calcium-
activated potassium channels, and the renal tubule, where
20-HETE promotes salt excretion by inhibiting Naþ -Kþ -ATPase
in proximal tubules and the Naþ -Kþ -2Cl cotransporter in the
thick ascending loop of Henle. 20-HETE is produced by CYP4A/
4F isoforms, which require molecular oxygen, NADPH, and free
arachidonic acid to catalyze the o-hydroxylation reaction.8 Thus,
20-HETE synthesis proceeds under normoxic conditions and is
dependent on extracellular signal-induced activation of phos-
pholipases A2, which release arachidonic acid from membrane
phospholipids. Once produced, 20-HETE is partially re-esterified
into phospholipids generating a membrane pool of preformed
20-HETE that is also accessible to phospholipases A2.9 These
features link the biosynthesis, storage, and 20-HETE release to
various signaling pathways triggered by vasoactive hormones and
growth factors.7 On the other hand, the same features may be
responsible for an excessive 20-HETE production under I/R
conditions, which stimulate phospholipase A2 activities in the
heart, brain, and kidney.10–12 Inhibition of 20-HETE synthesis
and action reduced I/R injury in the heart and brain.13,14
20-HETE overproduction mediated the cytotoxic and proapop-
totic effects of hypoxia on renal tubular epithelial cells.15 Vascular
CYP4A overproduction caused endothelial dysfunction and
hypertension by enhanced vasoconstriction, uncoupling of
endothelial nitric oxide (NO) synthase, and nuclear factor
(NF)-kB activation.16–18 These studies suggest that overproduc-
tion of 20-HETE has the potential to have a crucial role in the
whole series of events leading to postischemic AKI.
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We tested the hypothesis that targeting 20-HETE synthesis
and action may protect the kidney against I/R-induced AKI.
The experiments were performed in uninephrectomized
Lewis rats to partially mimic the situation after renal
transplantation, in which novel pharmacological interven-
tions are sorely needed to promote early graft function and
long-term survival. We used an inhibitor of CYP4A/4F
enzymes to block 20-HETE synthesis (HET0016)19 and
synthetic analogs to antagonize or mimic 20-HETE action.20
The analogs lack two of the four double bonds present in
20-HETE, rendering them more resistant against autoxida-
tion and metabolism by cyclooxygenases and lipoxy-
genases. The agonist, 20-hydroxyeicosa-5(Z),14(Z)-dienoic
acid (5,14-20-HEDE) and the antagonist, 20-hydroxyeicosa-
6(Z),15(Z)-dienoic acid (6,15-20-HEDE) differ only in
double-bond positions and otherwise share identical physi-
cochemical properties.
RESULTS
I/R-induced 20-HETE release
In a first series of experiments, we used isolated perfused
kidneys to analyze the effect of I/R on renal 20-HETE
production. The experiments were performed in the absence
(0.1% dimethylsulfoxide (DMSO) as vehicle control) or
presence of the CYP4A inhibitor HET0016 (200 nmol/l);
n¼ 6 per group. Under basal conditions, vehicle-perfused
kidneys constantly released low amounts of 20-HETE (0.16±
0.06 ng/ml) corresponding to about 0.8 ng/min at a flow
rate of 5 ml/min. Twenty min of global ischemia induced
a significant overproduction of 20-HETE (Figure 1a).
20-HETE release was increased more than fourfold during
the first 5 min of reperfusion to 0.69±0.12 ng/ml (Po0.001
vs basal levels) and remained elevated until the end of
the experiment (0.40±0.08 ng/ml). HET0016 significantly
reduced I/R-induced 20-HETE overproduction to o50%
(0.32±0.08 ng/ml at 5 min; Po0.05 vs vehicle control) and
mediated a complete decline to basal levels after 30 min of
reperfusion (Figure 1a).
In a second series of experiments, we analyzed the release
of 20-HETE in uninephrectomized animals under the
conditions described below for inducing I/R injury in vivo
(Figure 1b). Untreated control kidneys contained about 30 ng
20-HETE per g wet weight, of which more than 90% became
accessible only after alkaline hydrolysis. These data show that
the overwhelming part of 20-HETE was present in normal
kidneys esterified to membrane phospholipids. Forty-five
min of warm ischemia caused a strong increase of free
20-HETE in the kidneys pretreated with vehicle or 6,15-20-
HEDE (Po0.05 vs non-ischemic control, n¼ 5–6 per group).
In contrast, pretreatment with HET0016 resulted in sig-
nificantly lower free 20-HETE levels in the ischemic kidneys
(Po0.05 vs the vehicle and 6,15-20-HEDE groups, n¼ 5–6
per group). Reperfusion was associated with a strong decrease
in free 20-HETE and a concomitant increase of esterified
20-HETE in all groups, but most pronounced after HET0016
pretreatment (Figure 1b).
Role of 20-HETE in I/R-induced renal functional impairment
Increased serum creatinine and urea levels as well as
decreased creatinine clearance indicate a significant decline
in renal function, representative for our model of AKI
(Figure 2). In vehicle-treated animals, I/R induced an eight-
fold increase of the serum creatinine and urea levels and
reduced creatinine clearance to 20% compared with sham-
operated uninephrectomized controls (0.26±0.02 vs 1.37±
0.04, Po0.001, n¼ 8 per group). The vehicle itself (100 ml of
saline containing 1% DMSO) had no effect compared with
an animal group that did not receive any intrarenal infusion
(creatinine: 2.41±0.23 vs 2.54±0.77 mg/dl; urea: 287.8±
34.8 vs 303.2±76.13 mg/dl; creatinine clearance: 0.26±0.02
vs 0.25±0.09 ml/min; all comparisons were not significant;
eight vehicle treated vs six untreated animals).
I/R-induced impairment in renal function (Figure 2) was
significantly ameliorated by pretreatments with HET0016
(50 mg injection via the renal artery) or 6,15-20-HEDE
(20 mg injection). The creatinine clearance was improved to
0.63±0.12 ml/min with HET0016 (Po0.01 vs vehicle; n¼ 8
per group) and to 0.76±0.12 ml/min with 6,15-20-HEDE
20
-H
ET
E 
(ng
/m
l)
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
20
-H
ET
E 
(ng
/g)
60
40
20
0
NC VI VR AI AR HI HR
Esterified
Free
Animal group
#
#
#
#
*
*
$
$$$
#
#
#
*
#* #*
Time after ischemia
–5 min 5 min 10 min 15 min 30 min
IR+vehicle
IR+HET0016
Figure 1 | Ischemia/reperfusion (I/R)-induced release of
20-hydroxyeicosatetraenoic acid (20-HETE). (a) In isolated
perfused kidneys, I/R induced an increased release of 20-HETE that
was partially blocked by HET0016. Data are given as mean±s.e.m.
(n¼ 6 per group). #Po0.05 vs basal 20-HETE release 5min
before ischemia; *Po0.05 for vehicle vs HET0016.
(b) In uninephrectomized Lewis rats, 45min of warm ischemia
induced increased renal levels of free 20-HETE after pretreating
the animals with vehicle (VI group) or the 20-HETE antagonist,
6,15-20-HEDE (AI group) compared with non-ischemic controls
(NC group). Ischemia in the presence of HET0016 resulted in
significantly lower free 20-HETE levels (HI group). Free 20-HETE
levels were decreased and esterified 20-HETE levels were
increased 2 h after reperfusion (groups VR, AR, and HR).
Statistically significant differences with Po0.05 were observed as
indicated: *¼ vs free 20-HETE in NC; #¼ vs esterified 20-HETE in
NC; $¼ vs free 20-HETE in VI and AI.
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(Po0.01 vs vehicle; n¼ 8 per group). In contrast, 5,14-20-
HEDE (20 mg injection) did not improve renal dysfunction.
The 20-HETE agonist partially reversed the protective effect
of the CYP4A inhibitor as revealed by the animal group
receiving a combined treatment of HET0016 and 5,14-20-
HEDE. This reversal was significant for both serum urea
levels and creatinine clearance (each Po0.01 vs HET0016
alone; n¼ 8 per group).
Role of 20-HETE in I/R-induced renal tubular injury
I/R induced severe renal tubular damage as indicated by the
occurrence of flattened tubular epithelium, exfoliated tubular
epithelial cells, widened tubular lumina, hyaline cast forma-
tion, and necrotic tubules (Figure 3a). The degree of necrotic
renal injury was significantly higher in the outer medulla
(acute tubular necrosis (ATN) score: 2.50±0.20) compared
with renal cortex (1.33±0.12); Figure 3b and c.
The ATN scores were significantly reduced by administration
of HET0016 (outer medulla: 1.04±0.31, Po0.001 vs vehicle;
cortex: 0.58±0.27, Po0.05 vs vehicle). Also the 20-HETE
antagonist 6,15-20-HEDE exerted a strong protective effect and
reduced the ATN scores to 0.92±0.21 in the outer medulla and
to 0.41±0.16 in the renal cortex (both Po0.001 vs vehicle). In
contrast, tubular damage was as severe as in the vehicle control
after infusing the 20-HETE agonist. The combined administra-
tion of 5,14-20-HEDE and HET0016 trended to result in
enhanced ATN scores compared with HET0016 alone, however,
without reaching statistical significance (Figure 3).
Role of 20-HETE in I/R-induced apoptosis of tubular
epithelial cells
I/R-induced renal injury resulted in a strong increase of
apoptotic tubular epithelial cells (Figure 4a). Semiquantitative
evaluation showed that apoptosis was more pronounced in the
outer medulla (4.10±0.26% per field of view; FOV) than in the
renal cortex (1.87±0.27% per FOV; Figure 4c and b).
The number of apoptotic cells was strongly reduced by
HET0016 (outer medulla: 1.37±0.27%, cortex: 0.53±0.12%
per FOV; both Po0.001 vs vehicle control) or 6,15-20-HEDE
(outer medulla: 0.94±0.42%, cortex 0.52±0.21% per FOV;
both Po0.001 vs vehicle). In contrast, animals pretreated
with 5,14-20-HEDE showed a high degree of renal tubular
apoptosis not different from the vehicle control. 5,14-20-
HEDE reversed the antiapoptotic effect of HET0016
comparing animals pretreated with HET0016 alone or with
a combination of both drugs (Po0.01; Figure 4).
Role of 20-HETE in the postischemic inflammatory response
I/R induced pronounced renal inflammation as indicated by
a dense infiltration of monocytes/macrophages into the
damaged zones of the outer medulla and renal cortex
(Figure 5). Monocytes/macrophages were predominantly
located in the tubulointerstitium adjacent to injured tubules
and around small arteries (Figure 5a). Morphometric
quantification displayed higher cell counts in the outer
medulla (53.4±1.6 cells/high power field (HPF)) compared
with renal cortex (46.8±2.0 cells/HPF) of vehicle-treated
animals (Figure 5b and c).
Application of HET0016 attenuated the response by about
50% (outer medulla: 24.7±4.7 and cortex: 15.2±1.7 cells/
HPF, both Po0.001 vs vehicle control). The 20-HETE
antagonist, 6,15-20-HEDE, also markedly reduced ED1þ
infiltrates to 19.0±5.9 in the outer medulla and to 15.5±4.4
cells/HPF in the cortex (both Po0.001 vs vehicle). The 20-
HETE agonist, 5,14-20-HEDE, did not inhibit cell infiltration
and rather trended to further aggravate inflammation in the
renal cortex (51.7±2.4 cells/HPF, P¼ 0.132) and significantly
in the outer medulla (61.5±2.0 cells/HPF, Po0.05 vs vehicle
control). 5,14-20-HEDE clearly reversed the anti-inflamma-
tory effect of CYP4A inhibition (outer medulla: 42.6±1.9
and cortex 33.8±1.6 cells/HPF, both Po0.05 compared with
HET0016 alone).
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Figure 2 |Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in ischemia/reperfusion (I/R)-induced loss of renal function. Serum
levels of creatinine (a) and urea (b) and the creatinine clearance (c) were determined 2 days after reperfusion. HET0016 and 6,15-20-HEDE
significantly improved I/R-induced renal dysfunction, whereas 5,14-20-HEDE was not protective and partially reversed the beneficial
effect of HET0016. Data are given as mean±s.e.m. (n¼ 8 per group). Statistically significant differences with Po0.01 were observed as
indicated: *¼ vs Uni-Nx, #¼ vs IRþ vehicle, þ ¼ vs IRþ 5,14-20-HEDE, x¼ vs IRþHET0016 and y¼ vs IRþ 6,15-20-HEDE.
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20-HETE, I/R-induced renal hemodynamic changes, and
intrarenal oxygenation
Renal artery and vein occlusion caused an immediate
decrease in total renal blood flow, as well as of the Laser-
fluxes that characterize regional perfusion in the renal cortex
and medulla (Figure 6a–c). Moreover, cortical and medullary
pO2 instantly dropped to about 0.1 mm Hg followed by a
slow increase to about 2 mm Hg during 45 min of ischemia
(Figure 6d and e). Upon reperfusion, total renal blood flow
steeply increased to almost 50% and then slowly recovered to
about 90% of the baseline flow. Systemic mean arterial blood
pressure remained stable throughout the entire observation
period (baseline average 97.6±3.5 mm Hg). These features
were not significantly different, comparing rats receiving
intrarenal injections of vehicle or 6,15-20-HEDE before
inducing ischemia.
However, the two animal groups showed marked differ-
ences in the rate and extent of intrarenal reoxygenation
during the reperfusion phase (Figure 6d and e). In the renal
cortex and medulla of 6,15-20-HEDE-pretreated animals,
oxygen pressure rapidly reached and then even slightly
exceeded the baseline levels before ischemia. In the vehicle
group, the intrarenal pO2 recovered only partially and
reached 2 h after reperfusion about 80% (cortex) and 60%
(medulla) of the baseline values. In particular, reoxygenation
in medulla occurred with significant delay as compared with
the 6,15-20-HEDE group (Figure 6d). 6,15-20-HEDE also
significantly accelerated the recovery of medullary perfusion
that remained, however, below the baseline levels (Figure 6c).
The effect of the 20-HETE antagonist was less pronounced in
the cortex, in which the difference in regional Laser-fluxes did
not reach significance compared with vehicle (Figure 6b).
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Figure 3 |Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in ischemia/reperfusion (I/R)-induced tubular injury. (a) Representative
images of hematoxylin- and eosin-stained sections of the outer medulla of kidneys harvested from the different treatment groups 2 days
after inducing renal I/R injury. Original magnification 100 . (b, c) Evaluation of tubular necrosis in the outer medulla and renal cortex using
an acute tubular necrosis (ATN) score. HET0016 and 6,15-20-HEDE significantly ameliorated tubular damage, whereas 5,14-20-HEDE was not
protective. Significant differences with Po0.05 were observed as indicated: #¼ vs IRþ vehicle, þ ¼ vs IRþ 5,14-20-HEDE, x¼ vs
IRþHET0016 and y¼ vs IRþ 6,15-20-HEDE.
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DISCUSSION
We found that inhibiting the generation and action of
20-HETE can significantly ameliorate experimental AKI.
Treatments with a CYP4A/4F-inhibitor (HET0016) or a
20-HETE antagonist (6,15-20-HEDE) protected against I/R-
induced vascular inflammation, tubular injury, and loss of
renal function. In contrast, the structurally related 20-HETE
agonist (5,14-20-HEDE) did not improve renal I/R injury
but instead partially reversed the beneficial effects of
HET0016-mediated inhibition of 20-HETE synthesis.
Our data on the renal production of 20-HETE demon-
strate that this CYP-eicosanoid is indeed overproduced under
I/R conditions. Probably, both phospholipase-mediated
release of stored 20-HETE and de novo synthesis contributed
to the large increase in free 20-HETE that reached calculated
global concentrations of 50–80 nM in the ischemic kidneys.
20-HETE efficiently uncouples endothelial NO synthase and
activates nuclear factor-kB at concentrations as low as
1 nM.17,18 Moreover, 20-HETE significantly constricts rat
renal afferent arterioles with a threshold concentration of
1 nM.21 Thus, the amounts of free 20-HETE present in
ischemic kidneys appear more than sufficient to trigger
important early events in the development of AKI, such as
endothelial dysfunction, inflammation, and vasoconstriction.
Moreover, studies in the heart indicated that 20-HETE acts as
an inhibitor of adenosine triphosphate (ATP)-sensitive
potassium (KATP)-channels.
22 Opening of mitochondrial
and plasmalemmal KATP channels is a key component of
survival mechanisms in several cell types23 and also improves
I/R-induced renal injury.24
Our pharmacological interventions aimed at inhibiting
20-HETE synthesis and blocking 20-HETE action were also
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Figure 4 |Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in ischemia/reperfusion (I/R)-induced apoptosis of tubular epithelial
cells. (a) Representative images of outer medullary sections stained using the TdT-mediated dUTP nick end labeling assay to evaluate
the presence of apoptotic nuclei. Original magnification 400 . (b, c) Quantification of apoptosis in the outer medulla and renal cortex
by counting the percentage of apoptotic cells per high power view field. HET0016 and 6,15-20-HEDE significantly protected
against I/R-induced apoptosis, whereas 5,14-20-HEDE did not. 5,14-20-HEDE significantly reversed the antiapoptotic effect of HET0016.
Significant differences with Po0.01 were observed as indicated: *¼ vs Uni-Nx; #¼ vs IRþ vehicle; þ ¼ vs IRþ 5,14-20-HEDE; x¼ vs
IRþHET0016; y¼ vs IRþ 6,15-20-HEDE.
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effective in preserving renal function. The data on necrosis,
inflammation, and apoptosis suggest that blockade of
20-HETE action may be more promising than inhibition of
20-HETE synthesis in preventing renal injury. This difference
may be due to the fact that HET0016 only mediates
inhibition of 20-HETE de novo synthesis, whereas 6,15-20-
HEDE has the capacity to antagonize the action of total free
20-HETE including preformed 20-HETE released from
membrane stores under ischemia. We found that inhibition
of 20-HETE actions significantly accelerates and improves
medullary and cortical reoxygenation in the early reperfusion
phase. In this way, 20-HETE blockade largely reduces the
time that these regions are exposed to severe tissue hypoxia,
despite the onset of reperfusion. Intrarenal oxygenation is
regulated by a variety of factors including local perfusion,
local oxygen consumption, and arterial-to-venous oxygen
shunting.25 In our model, inhibition of 20-HETE action
indeed promotes the recovery of medullary blood flow.
This finding is in agreement with the vasoconstrictor role
of 20-HETE in renal arterioles21 and with the capacity of
20-HETE to reduce the formation of vasodilatory NO,17
as discussed above. As NO inhibits CYP enzymes,
NO-deficiency leads to enhanced 20-HETE synthesis.26 These
20-HETE/NO interactions may prompt a vicious cycle that
progressively impairs endothelial function and results in
persistent vasoconstriction during I/R. Surprisingly, we found
Control IR+vehicle IR+5,14-20-HEDE
IR+6,15-20-HEDE IR+5,14-20-HEDE+HET0016IR+HET0016
*
*#+
*
*#+*#+ *#+
*#xy
*xy
*#+xy
*#+xy
ED
1+
 c
el
ls
 (c
ell
s/H
PF
)
Un
i-N
x
IR+
ve
hic
le
IR+
HE
T0
01
6
IR+
6,1
5-2
0-H
ED
E
IR+
5,1
4-2
0-H
ED
E
IR+
5,1
4-2
0-H
ED
E+
HE
T0
01
6
Un
i-N
x
IR+
ve
hic
le
IR+
HE
T0
01
6
IR+
6,1
5-2
0-H
ED
E
IR+
5,1
4-2
0-H
ED
E
IR+
5,1
4-2
0-H
ED
E+
HE
T0
01
6
70
60
50
40
30
20
10
0
ED
1+
 c
el
ls
 (c
ell
s/H
PF
) 70
60
50
40
30
20
10
0
Figure 5 |Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in renal inflammation. (a) Representative images of outer medullary
sections stained for ED1þ monocytes/macrophages to evaluate inflammatory cell infiltration as induced by renal ischemia/
reperfusion (I/R) injury in the different animal groups. Original magnification 100 . (b, c) Quantification of inflammatory
cell infiltration in the outer medulla and renal cortex by counting the number of ED1þ cells per high power view field (HPF). HET0016 and
6,15-20-HEDE significantly decreased I/R-induced inflammatory cell infiltration. In contrast, 5,14-20-HEDE significantly increased the
inflammatory response in the outer medulla and reversed the anti-inflammatory effect of HET0016 both in the outer medulla and renal
cortex. Significant differences with Po0.01 were observed as indicated: *¼ vs Uni-Nx; #¼ vs IRþ vehicle; þ ¼ vs IRþ 5,14-20-HEDE; x¼ vs
IRþHET0016; y¼ vs IRþ 6,15-20-HEDE.
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that reoxygenation in the presence of the 20-HETE
antagonist leads to intrarenal pO2 values that even exceeded
those measured under baseline conditions. Although the
actual mechanisms are unclear, we were interested to note
that 20-HETE-mediated changes in NO bioavailability could
possibly also affect tubular oxygen consumption, as NO may
inhibit sodium reabsorption and increase the efficiency of
nephron oxygen utilization.25
The results of our study are paralleled by previous studies
in the heart13,22 and brain,14 suggesting that inhibition of
20-HETE generation and action may provide a general
therapeutic option for the prevention and treatment of
ischemic organ injury. However, Roman and associates
recently reported that HET0016 exacerbated and 20-HETE
agonists attenuated I/R-induced renal injury.27 These findings
that obviously contradict our results may be related to the use
of different models (Sprague–Dawley rats with bilateral
clamping of two kidneys vs uninephrectomized Lewis inbred
rats in our study) and treatment forms (systemic high-dose
compared with local low-dose drug application). Moreover,
Regner et al.27 solely used 20-HETE agonists and did not
compare their effects with those of 20-HETE antagonists as
performed in our study. A specific concern associated with
high systemic HET0016 levels may arise from the potential of
this CYP-inhibitor to inhibit not only 20-HETE synthesis,
but also the o-hydroxylation and inactivation of leukotriene
B4 that functions as neutrophil chemoattractant, and thereby
aggravates ischemic renal damage.28
However, the contradictory findings most probably reflect
the complex vascular and tubular roles of 20-HETE in the
kidney. This very problem also led to apparently contra-
dictory findings on the pro- and antihypertensive roles of
20-HETE. Spontaneously hypertensive rats and salt-sensitive
Dahl rats develop hypertension that is associated with either
overproduction or deficiency of 20-HETE.29,30 This apparent
contradiction has been largely resolved recognizing that
vascular overproduction of 20-HETE induces vasoconstric-
tion, endothelial dysfunction, and hypertension, whereas
tubular deficiency of 20-HETE impairs salt excretion and
thus also causes hypertension. This dual and site-specific
role of 20-HETE is similarly reflected by opposite effects
of HET0016 in different models, namely, reduction of
blood pressure in androgen- and cyclosporin A-hypertensive
rats vs induction of salt-sensitive hypertension in normal
Sprague–Dawley rats.31–33
We propose that 20-HETE may have different roles during
AKI development. We intentionally injected low doses (mg/kg
range) of HET0016 and of the 20-HETE analogs directly into
the renal artery before occlusion, to achieve effective drug
levels during ischemia with rapid washout upon reperfusion.
This strategy blocked the effects of 20-HETE overproduction.
Regner et al.27 used high doses of HET0016 and 5,14-20-
HEDE (mg/kg range) subcutaneously, resulting in high
systemic drug levels that acted not only during ischemia
but also during reperfusion. Under these conditions,
20-HETE agonists may protect the kidney against I/R injury
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Figure 6 |Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in ischemia/reperfusion (I/R)-induced renal hemodynamic changes
and local tissue oxygenation. (a–c) Time course of relative changes in total renal blood flow (average baseline 2.9±0.3ml/min),
local cortical Laser-flux, and local medullary Laser-flux. (d, e) Time course of local cortical pO2 and local medullary pO2.
Renal ischemia (from time 0–45min) was induced 5min after pretreating the animals by intrarenal injections of vehicle or 6,15-20-HEDE
followed by 2 h of reperfusion (n¼ 7 animals per group). Note the significantly accelerated and improved recovery of medullary perfusion
(c) and of the cortical and medullary oxygenation (d and e) in the 6,15-20-HEDE compared with the vehicle-treated animals.
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primarily in the reperfusion phase by inhibiting sodium
reabsorption, thereby limiting tubular oxygen consumption.
Roman and associates also reported that HET0016 blocked,
whereas 20-HETE exacerbated, the cytotoxic and proapop-
totic effects of hypoxia on tubular epithelial cells.15 These
in vitro data are in agreement with the results of our in vivo
study. Taken together, the findings suggest a rather strict
therapeutic window in terms of dosage and timing that
determines the outcome of pharmacological interventions
targeting the complex CYP/20–HETE system in the kidney.
We believe our data could offer a therapeutic perspective.
I/R-induced AKI is common after cardiovascular and kidney
transplant surgery, clinical situations that could be amenable
to the experimental approaches used here. Noteworthy,
a recent clinical study demonstrated that the extent of
20-HETE release occurring within the first 5 min of allograft
reperfusion is a negative predictor of post-transplant allograft
function.34 However, further studies are required to strictly
define the therapeutic window for 20-HETE antagonists or
agonists. Moreover, cell-type-specific drug delivery could
avoid potential adverse effects that are clearly predictable
recognizing the site-specific and partially opposite effects of
20-HETE in the kidney. These conclusions may apply in
general to all therapeutic strategies aimed at targeting
20-HETE synthesis and action, as this CYP-eicosanoid
contributes to the development of endothelial dysfunction,
vascular inflammation, uncontrolled angiogenesis, hyperten-
sion, and ischemic organ injury, but is nonetheless required
to maintain renal tubular function.35
METHODS
Animal model
Inbred male Lewis (Lew, RT1) rats, aged 10 weeks, were kept under
standard conditions. Local authorities approved all experimental
procedures according to American Physiological Society guidelines.
After removal of the right kidney, HET0016 (50 mg), 6,15-20-HEDE
(20mg), 5,14-20-HEDE (20 mg), a combination of HET0016 (50 mg)
and 5,14-20-HEDE (20 mg) or vehicle (n¼ 8 per group) were
administered in the left renal artery. HET0016 was purchased from
Cayman Chemicals (Biomol GmbH, Hamburg, Germany) and the
20-HETE analogs were synthesized as described previously.20 Stock
solutions were prepared in DMSO and further diluted 100-fold with
0.9% NaCl solution to give the indicated amounts in a volume of
100ml for intrarenal injection. A quantity of 100 ml of 0.9% NaCl
containing 1% DMSO served as vehicle control. The remaining left
kidney was exposed to 45 min of warm ischemia by clamping renal
artery and vein 5 min after intrarenal drug administration. One day
after I/R, animals were set into metabolic cages for urine collection
over a period of 24 h. Organs were harvested and blood samples
were taken 2 days post-I/R.
20-HETE release
In isolated perfused kidneys. The renal artery of the left
isolated kidney was cannulated and the organ was perfused in an
organ chamber at 37 1C at constant flow (5 ml/min).36 The
oxygenated (95% O2–5% CO2) perfusion buffer contained either
vehicle (0.1% DMSO) or HET0016 (200 nmol/l); n¼ 6 kidneys per
group. After an equilibration period of 20 min, perfusion was
stopped for 20 min to mimic warm ischemia followed by 30 min of
reperfusion. The total renal outflow was collected in 5 min intervals
before and up to 30 min after inducing ischemia. 20-HETE-d6
(Cayman Chemicals) was added to the perfusate samples as internal
standard. Solid phase extraction and quantification of 20-HETE by
liquid chromatography tandem mass spectrometry (Lipidomix
GmbH, Berlin, Germany) were performed as described previously.37
In vivo during I/R. Rats were uninephrectomized, pretreated
with vehicle, 6,15-20-HEDE or HET0016, and ischemia was induced
in the remaining left kidney as described above. The ischemic
kidneys were removed and immediately frozen in liquid nitrogen
either directly after 45 min of ischemia or 2 h after reperfusion
(n¼ 5–6 animals per treatment group and time point). Total kidneys
were then pulverized in liquid nitrogen and 30 mg aliquots were
used for subsequent liquid chromatography tandem mass spectro-
metry analysis.37 To differentiate between esterified and free
20-HETE, the samples were extracted with or without previous
alkaline hydrolysis.
Renal pathology, immunohistochemistry, and morphometry
Formalin-fixed and paraffin-embedded renal sections (2 mm) stained
with hematoxylin and eosin and periodic acid-Schiff (PAS) were
graded according to previously described score for ATN.38 Renal
apoptosis was examined in fluorescein-stained formalin-fixed renal
sections using the in situ Cell Death Detection Kit (Roche
Diagnostics, Indianapolis, IN). TdT-mediated dUTP nick end
labeling-positive cells were visualized under a fluorescence micro-
scope (Zeiss Axio Imager A1, Jena, Germany) and quantified using a
digital imaging system (Zeiss Axiocam HR with Axiovision 4.4
software). The positively immunostained area was binarized and
calculated as percent per FOV at 400 magnification in renal cortex
and outer medulla. Monocyte staining was performed with the
monoclonal mouse antibody ED-1 (Serotec, Oxford, UK) and
visualized using the alkaline-phosphatase-anti-alkaline-phosphatase
method. The number of ED1þ cells was scored in 10 randomly
chosen FOVs in cortex and outer medulla. Results were expressed as
mean±s.e.m. of cells/FOV at 400 magnification HPF.
In vivo measurement of renal hemodynamics and tissue
oxygenation
Urethane intraperitoneally (1.2 g/kg body mass; Sigma, Taufkirchen,
Germany) caused anesthesia. Rats were maintained at 37 1C and
breathed spontaneously. After right nephrectomy, a non-obstructive
catheter was placed into the abdominal aorta (tip at the level of the
remaining left renal artery) for recording of arterial blood pressure
(Gould, Valley View, OH) and for intrarenal drug administration.
A soft ribbon was loosely slung around the left renal artery and vein.
An ultrasound transit time flow probe (Transonic Systems,
Ithaca, NY) was positioned around the left renal artery to measure
renal blood flow. Two combined optical Laser-Doppler-flux- and
pO2-probes attached to an OxyLite/OxyFlo-apparatus (Oxford
Optronics, Oxford, UK) were used to measure local flux of
erythrocytes (Laser-Doppler-signal) and local pO2. As described
previously,39 by means of micromanipulators, one of the combined
probes was inserted into the kidney to a depth of approximately
2 mm, thus providing values for the subjacent cortical tissue,
whereas the tip of the other probe was advanced to approximately
4 mm, thus providing values for the subjacent medullary tissue.
After obtaining baseline values, intrarenal bolus injections of either
6,15-20-HEDE (20 mg) or vehicle (n¼ 7 rats per group) were
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performed. Five min later, renal ischemia was initiated by tightening
the ribbon around the left renal artery and vein, and ischemia was
maintained for 45 min. All parameters were continuously recorded
at a sampling rate of 50 Hz until 2 h after the end of ischemia time.
Statistical analysis
Statistical analysis was performed using non-parametric Mann–
Whitney U-test with paired comparisons for more than two groups.
Po0.05 was considered significant. All statistical tests were performed
using SPSS 11.5 for Windows (SPSS, Chicago, IL).
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